FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2325795779> ?p ?o ?g. }

• W2325795779 endingPage "S15" @default.
• W2325795779 startingPage "S15" @default.
• W2325795779 abstract "The practice of dosing 5-aminosalicylates in divided doses for the treatment of ulcerative colitis (UC) began with sulfasalazine and was driven by sulfapyridine toxicity. This convention and the assumption that dosing multiple times a day is necessary to treat UC had not been challenged until recently. To determine the efficacy and safety of once daily (QD) dosing of delayedrelease mesalamine (400mg tablets) compared to twice daily (BID) dosing for maintaining remission in patients with UC. A multi-center, randomized, investigator-blinded, 12-month, activecontrol trial (QDIEM) was conducted to assess the non-inferiority of QD versus BID dosing for maintaining clinical remission in patients with UC. Patients who had been maintained in clinical remission (Simple Clinical Colitis Activity Index [SCCAI] score ≤ 2 points) on mesalamine doses ranging from 1.6 g/day to 2.4 g/day were randomized to either a QD or BID dosing regimen at the same total daily dose that the patients had been maintained on prior to study entry. The primary endpoint was the percent of patients remaining in remission at Month 6 for QD dosing as compared with BID dosing. Relapse was defined as an SCCAI score ≥ 5 points. In order to assess whether non-inferiority was met a 95% confidence interval for the difference between the BID and QD groups was computed. Safety parameters included investigator reports of Serious Adverse Events (SAEs) and withdrawals due to adverse events. One thousand twenty three (1023) patients with UC in clinical remission were randomized and dosed. Seventy percent (70%) of patients received 2.4 g/day, 28% received 1.6 g/day and 2% received 2.0 g/day. The primary objective of noninferiority was met with 90.5% (428/473) and 91.8% (435/474) of patients dosed QD and BID, respectively, remaining in clinical remission at Month 6 (95% CI for BID-QD, -2.3, 4.9). At Month 12, 85.4% (379/444) of patients receiving QD dosing had maintained clinical remission, compared with 85.4% (380/445) of patients receiving BID dosing (95% CI for BID-QD, -4.6, 4.7). The number of SAEs and withdrawals due to AEs were similar between the QD and BID dosing regimens. In this study, once-daily dosing of delayed-release mesalamine (400mg tablets) at doses of 1.6-2.4 g/day was shown to be as effective as twice daily dosing for maintenance of clinical remission in patients with UC." @default.
• W2325795779 created "2016-06-24" @default.
• W2325795779 creator A5005220122 @default.
• W2325795779 creator A5019936369 @default.
• W2325795779 creator A5032150391 @default.
• W2325795779 creator A5042813574 @default.
• W2325795779 creator A5051654126 @default.
• W2325795779 creator A5052966051 @default.
• W2325795779 creator A5061317637 @default.
• W2325795779 creator A5073750919 @default.
• W2325795779 creator A5080884445 @default.
• W2325795779 creator A5091400546 @default.
• W2325795779 date "2009-12-01" @default.
• W2325795779 modified "2023-10-05" @default.
• W2325795779 title "Once daily dosing of delayed-release oral mesalamine for maintenance of remission of Ulcerative Colitis (the QDIEM Trial): 6 and 12 month results" @default.
• W2325795779 doi "https://doi.org/10.1097/00054725-200912002-00041" @default.
• W2325795779 hasPublicationYear "2009" @default.
• W2325795779 type Work @default.
• W2325795779 sameAs 2325795779 @default.
• W2325795779 citedByCount "0" @default.
• W2325795779 crossrefType "journal-article" @default.
• W2325795779 hasAuthorship W2325795779A5005220122 @default.
• W2325795779 hasAuthorship W2325795779A5019936369 @default.
• W2325795779 hasAuthorship W2325795779A5032150391 @default.
• W2325795779 hasAuthorship W2325795779A5042813574 @default.
• W2325795779 hasAuthorship W2325795779A5051654126 @default.
• W2325795779 hasAuthorship W2325795779A5052966051 @default.
• W2325795779 hasAuthorship W2325795779A5061317637 @default.
• W2325795779 hasAuthorship W2325795779A5073750919 @default.
• W2325795779 hasAuthorship W2325795779A5080884445 @default.
• W2325795779 hasAuthorship W2325795779A5091400546 @default.
• W2325795779 hasBestOaLocation W23257957791 @default.
• W2325795779 hasConcept C126322002 @default.
• W2325795779 hasConcept C168563851 @default.
• W2325795779 hasConcept C197934379 @default.
• W2325795779 hasConcept C203092338 @default.
• W2325795779 hasConcept C2777288759 @default.
• W2325795779 hasConcept C2779134260 @default.
• W2325795779 hasConcept C2779383735 @default.
• W2325795779 hasConcept C2780479503 @default.
• W2325795779 hasConcept C71924100 @default.
• W2325795779 hasConceptScore W2325795779C126322002 @default.
• W2325795779 hasConceptScore W2325795779C168563851 @default.
• W2325795779 hasConceptScore W2325795779C197934379 @default.
• W2325795779 hasConceptScore W2325795779C203092338 @default.
• W2325795779 hasConceptScore W2325795779C2777288759 @default.
• W2325795779 hasConceptScore W2325795779C2779134260 @default.
• W2325795779 hasConceptScore W2325795779C2779383735 @default.
• W2325795779 hasConceptScore W2325795779C2780479503 @default.
• W2325795779 hasConceptScore W2325795779C71924100 @default.
• W2325795779 hasLocation W23257957791 @default.
• W2325795779 hasOpenAccess W2325795779 @default.
• W2325795779 hasPrimaryLocation W23257957791 @default.
• W2325795779 hasRelatedWork W2082034492 @default.
• W2325795779 hasRelatedWork W2087566648 @default.
• W2325795779 hasRelatedWork W2349558415 @default.
• W2325795779 hasRelatedWork W2365116619 @default.
• W2325795779 hasRelatedWork W2392108285 @default.
• W2325795779 hasRelatedWork W2398431999 @default.
• W2325795779 hasRelatedWork W3028661770 @default.
• W2325795779 hasRelatedWork W3028966127 @default.
• W2325795779 hasRelatedWork W3032812622 @default.
• W2325795779 hasRelatedWork W4254987087 @default.
• W2325795779 hasVolume "15" @default.
• W2325795779 isParatext "false" @default.
• W2325795779 isRetracted "false" @default.
• W2325795779 magId "2325795779" @default.
• W2325795779 workType "article" @default.